carocell bio


Carocell Bio is a leader in inflammation technologies and believes its pipeline has the potential to provide future generations of novel, targeted anti-inflammatory therapies

Company profile

Carocell Bio is preclinical-stage biopharmaceutical company, focused on the development and commercialization of anti-inflammatory therapies and committed to bringing novel, life-changing treatments to patients with atopic dermatitis, ulcerative colitis and other inflammatory conditions. Carocell Bio believes its portfolio of products, which combine peptides and nanoparticle delivery technology, has the potential to deliver efficacy and safety benefits over existing standards of care and provide new approaches in the treatment of inflammation.

Revenue generating within 3 years

Carocell Bio Ltd is an ambitious company aiming to be revenue-generating within 3 years. We are driven to create new, more safe and effective treatments for serious inflammatory diseases that will make the world a better place and you can play a part in that process.

What will your investment do?

Carocell is seeking a total of $10m 'Series A' investment over the next 3 years to take the lead compound through to approved IND/CTA. The $10m dollars consists of:

  • $1m to demonstrate that the peptide compounds work in human inflammatory tissue samples
  • $9m to do everything required pre-clinically to drive the Lead Compound through to approved IND/CTA.

Summary of what the initial $1m (£760,000) investment will enable:

  • Drug manufacture and initial formulation development to facilitate future development
  • Assess anti-inflammatory properties of the compounds in explanted human tissue samples (AD/Burns/IBD) 
  • Deliver human tissue ex-vivo proof of concept required for drug development aiding further investment and growth
  • Select the lead compound for development in the lead indication
    • Most efficacy, lowest dose
    • Market assessment
    • Discussion with colleagues

Summary of what the $9m (£7.6m) investment will enable:

  • All the studies and investigations required to drive the lead compound through to regulatory approved IND/CTA. This will include Safety Pharmacolgy, Immugenicity studies, Toxicology and GMP formulation and manufacture for clinical trials.
  • Set up the 'Adaptive Development Committee' to devise and gain 'global' approval for the proposed Adaptive Clinical Development Plan (aCDP) through to NDA/MAA

Summary of what the 'Series B' $6.5m (£5.14m) investment will enable:

  • Acquisition of the peptide patents (Exact amount has been confirmed)



timeline for bridge biotech research and development

Why invest now?

Investing in our research at this relatively early stage means that your returns have the potential to be higher when products go to market. An equity share of the business now will have the potential to be far higher than at a later stage when much of the equity has been taken. 

Incentives and tax breaks

Government backed tax schemes such as SEIS and EIS are available to assist a business or individual wishing to invest in a company like Carocell Bio. Read more below.

Available schemes for investors

Seed Enterprise Investment Schemes (SEIS) and Enterprise Investment Schemes (EIS) are schemes designed to encourage investment in small or medium sized companies. They offer tax relief to individual investors who buy new shares in the company. Small companies whilst being higher risk can grow very quickly and have the potential for large returns.

Seed Enterprise Investment Scheme (SEIS) tax breaks

The Seed Enterprise Investment Scheme was set up in 2012 and is very similar to EIS but was designed for investing in even smaller companies, and providing even more generous tax breaks.
The maximum workforce and gross assets allowable under EIS are 250 staff and £15 million respectively, SEIS has lower limits of 50 staff and £200,000 gross assets. Businesses must also be less than two years old (there are no age restrictions under EIS).

SEIS tax breaks are as follows:

  • Income tax relief of 50 per cent
  • No capital gains tax to pay on profits
  • No inheritance tax
  • Extra relief called capital gains reinvestment relief -  useful to you if you have recently paid capital gains tax on other investments. You can reclaim up to 50 per cent of the tax paid if you reinvest that money into SEIS

Enterprise Investment Scheme (EIS) tax breaks

The UK government set up the Enterprise Investment Scheme in 1994 and offers a number of tax breaks to investors. Here are some key points and features:

  • Income tax relief of 30%.
  • No capital gains tax on any profits you make from an EIS investment.
  • If you make a loss on your investment, you can offset that loss against income tax. 
  • No inheritance tax to pay on shares bought through EIS.
  • To be eligible for EIS reliefs, you generally have to hold the shares for at least three years before selling them.
  • You still have to pay tax on any dividends and you can’t be connected to the company or have a stake of more than 30 per cent of it.
  • You can invest a maximum of £1 million each year through EIS.

Help with gaining access to the SEIS and EIS schemes

If you invest through an angel investor network or an equity crowdfunding website, they should be able to help with the paperwork to access your EIS or SEIS benefits.

For more information about these schemes, please visit the HMRC website via links below:

SEIS scheme HMRC information
EIS scheme HMRC information



Talk to us

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.

bridge biotec facebookbridge biotec twitterbridge biotec linkedinbridge-youtube-60x60.png


UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

USA Office

Carocell Bio, Inc.
500 Delaware Avenue
Ste#1, 1960
DE 19899

UK Office

©2018 Carocell Bio Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
SK10 4TG